ArticleSchizophrenia bulletin2026
Multi-Omic Insight Into the Molecular Networks of Mitochondrial Dysfunction in the Pathogenesis of Schizophrenia.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background and hypothesisSchizophrenia is a complex psychiatric disorder with potential links to mitochondrial dysfunction, but the underlying molecular mechanisms remain unclear. We aimed to investigate the relationship between genes encoding proteins involved in mitochondrial function and schizophrenia through multi-omic analyses. STUDY
designWe analyzed blood-derived methylation, expression, and protein quantitative trait loci data integrated with schizophrenia genetic associations. We employed summary-data-based Mendelian randomization and colocalization analyses to identify potential associations. Phenome-wide association studies and molecular docking explored target druggability. STUDY
resultsWe identified ACADVL, encoding very long-chain specific acyl-CoA dehydrogenase, as associated with schizophrenia across methylation, expression, and protein levels. Higher ACADVL methylation was associated with increased schizophrenia risk, while higher expression and protein levels were protective. Phenome-wide analyses showed no significant associations with other traits and molecular docking showed good binding affinity between ACADVL and bisphenol A and perfluorooctanoic acid. Drug repurposing identified cholic acid, chenodeoxycholic acid, and deoxycholic acid as potential ACADVL-targeting agents.
conclusionsOur blood-based multi-omic analyses suggest ACADVL plays a role in schizophrenia pathophysiology. ACADVL represents a promising drug target for schizophrenia. Further validation and clinical trials are needed to explore ACADVL-based treatments for schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.